Skip to main content
Home > SciBX on Science > Cover Story

Chronological Index of SciBX: The Science-Business eXchange: Cover Story

SciBX: The Science-Business eXchange Current Issue
  • Figure 1: Exercise messenger. Dana-Farber Cancer Institute

    Browning fat Figure 1. Exercise messenger. Dana-Farber Cancer Institute researchers have identified a new hormone, irisin, which mediates some of the benefits exercise has on metabolism. Exercise induces increased …

    Published on 2/2/2012
  • Browning fat

    Dana-Farber researchers have identified a hormone, irisin, that converts white fat into brown-like fat in mice. Ember Therapeutics has licensed the findings and is generating stabilized irisin variants for obesity and …

    Published on 2/2/2012
  • Macrocycles by the trillions

    Japanese researchers have developed a method for creating large libraries of N-methylated peptide macrocycles. PeptiDream Inc. has exclusively licensed the technology and set up collaborations with six pharmas.

    Published on 1/26/2012
  • Figure 1: Making macrocycles RaPID-ly

    Macrocycles by the Trillions Figure 1. Making macrocycles RaPID-ly. A team from The University of Tokyo has developed a method called RaPID for generating libraries of trillions of N-methylated peptide macrocycles …

    Published on 1/26/2012
  • Spreadin' the news

    SciBX's roundup of 2011 public-private partnership data shows the emergence of New York as a translational hub, the impact of nongovernmental funding on infectious disease research compared with the more muted VC …

    Published on 1/19/2012
  • Figure 1: Breakdown of global public-private partnerships by companies (I) and institutions (II)

    Spreadin' the News Figure 1. Breakdown of global public-private partnerships by companies (I) and institutions (II). Percentages are out of total number of public-private partnerships worldwide; bracketed values are …

    Published on 1/19/2012
  • Figure 2: Regional breakdown of companies and institutions involved in public-private partnerships in the top six U.S. states (I), top five European countries (II) and top five ...

    Spreadin' the News Figure 2. Regional breakdown of companies and institutions involved in public-private partnerships in the top six U.S. states (I), top five European countries (II) and top five Asian countries (III…

    Published on 1/19/2012
  • Figure 3: Breakdown of therapeutic areas covered by seed or series A financing (I) and public-private partnerships in 2011 (II)

    Spreadin' the News Figure 3. Breakdown of therapeutic areas covered by seed or series A financing (I) and public-private partnerships in 2011 (II). For (I), percentages are out of total financing events across all …

    Published on 1/19/2012
  • Table 1: Leaders in the number of public-private partnerships

    Spreadin' the News Table 1. Leaders in the number of public-private partnerships. U.S. institutes were involved in over half of the reported public-private partnerships (PPPs) in 2011, with such institutes taking …

    Published on 1/19/2012
  • Table 2: Top five public-private partnerships by value

    Spreadin' the News Table 2. Top five public-private partnerships by value. Three of the five largest public-private partnerships (PPPs) in 2011 are valued at $100 million or more. Listed PPPs do not include award and…

    Published on 1/19/2012
  • Table 3: Top five venture financing rounds for companies founded in 2011

    Spreadin' the News Table 3. Top five venture financing rounds for companies founded in 2011. The five largest series A rounds for companies founded in 2011 went to those with U.S. operations. Among the 31 companies …

    Published on 1/19/2012
  • VCAM-1 engine drives bone metastases

    A team led by Princeton researchers has shown that inhibiting vascular cell adhesion molecule-1/integrin alpha4 signaling could prevent bone metastases of breast cancer, thus handing companies with integrin alpha4 …

    Published on 1/12/2012
  • No place like inflammasome

    Researchers at Virginia Commonwealth University have found that inhibiting inflammasome formation with P2X7 antagonists could help prevent heart failure following acute myocardial infarction. The findings point to a …

    Published on 1/5/2012
  • Figure 1: Inflammasome activation pathway

    No place like inflammasome Figure 1. Inflammasome activation pathway. Acute myocardial infarction (AMI) causes the release of danger signals including damage-associated molecular pattern molecules (DAMPs) and ATP in …

    Published on 1/5/2012
  • Splicing out BRAF's resistance

    U.S. researchers have uncovered a mechanism by which melanomas expressing mutant BRAF acquire resistance to targeted drugs. The findings mark the first time a splice variant has been implicated in cancer drug resistance…

    Published on 12/15/2011
  • Figure: Complement's vicious cycle in osteoarthritis

    Big MAC attack in osteoarthritis Figure 1. Complement's vicious cycle in osteoarthritis. Joint damage can activate a self-perpetuating cycle of complement activation and cartilage damage that leads to osteoarthritis.…

    Published on 12/8/2011
  • Big MAC attack in osteoarthritis

    An international team has shown that inhibiting the complement system could help slow disease progression in osteoarthritis, thus handing a potentially disease-modifying strategy to companies developing complement 5 …

    Published on 12/8/2011
  • Turning back the malarial hordes

    Researchers from the Wellcome Trust Sanger Institute have identified a host receptor, basigin Ok blood group, that could be a good candidate for a vaccine against blood-stage malaria infection. The vaccine could be more…

    Published on 12/1/2011
  • Dampening neuroinflammation

    A California team has shown that inhibiting MAGL reduces neuroinflammation in a mouse model of Parkinson's disease. The researchers are now investigating the small molecule's effects in other neurodegenerative and …

    Published on 11/17/2011
  • Figure: Connecting cannabinoid and prostaglandin pathways

    Dampening neuroinflammation Figure 1. Connecting cannabinoid and prostaglandin pathways. A team led by researchers from The Scripps Research Institute and the University of California, Berkeley have shown that …

    Published on 11/17/2011
  • Figure 1: Putting a bias into antipsychotics

    Cover Story: Arrestin Psychosis Figure 1. Putting a bias into antipsychotics. A team from The University of North Carolina at Chapel Hill and Duke University has designed a class of antipsychotic compounds called b-…

    Published on 11/10/2011
  • Arrestin psychosis

    Duke and UNC Chapel Hill researchers have used the drug Abilify as a scaffold to design a new class of antipsychotics that showed fewer side effects in mice. The researchers are negotiating a licensing deal for the …

    Published on 11/10/2011
  • Scanning for oncogene addiction

    Stanford researchers have developed a computational approach to analyzing CT scan images that they think could be better than biopsy for predicting patient response to targeted cancer therapies. The team now plans to …

    Published on 11/3/2011
  • Much ado about TDO

    German researchers have shown that tryptophan 2,3-dioxygenase can promote tumor progression and immune escape through the degradation of tryptophan into kynurenine, giving tumors a second immune escape pathway in …

    Published on 10/27/2011
  • Figure: Model for TDO-derived kynurenine signaling through AHR

    Cover Story: Much ado about TDO Figure 1. Model for TDO-derived kynurenine signaling through AHR. The tryptophan metabolite kynurenine is an endogenous ligand for the aryl hydrocarbon receptor (AHR) that can promote …

    Published on 10/27/2011

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

SciBX: Science-Business eXchange

BioCentury's weekly translational science journal, published in collaboration with Nature Publishing Group:

  • Selects from hundreds of scientific papers published each week to identify early opportunities for investment, alliances and partnerships
  • Reports on the most commercially relevant developments